Adult height in t h e GE-patient i s only 160.5cm. Body p r o p o r t ions(n-3) a r e a s in NG ( s i t t i n g height (SH)t0.8, s u b i s c h i a l leg height(S1LH)t 0.6SD).Compared t o NB, t h e l e g s a r e r e l a t i v e l y s h o r t (SH-0.4,SILH-0.9SD).Tfm-patients provide a model t o study e s t r o g e n e f f e c t s without i n t e r f e r e n c e of androgens.1t i s concluded t h a t in NG t h e pubertal growth s p u r t a l s o i s mostly due t o t h e a c t i o n of e s t r o g e n s r a t h e r than of adrenal androgens, and t h a t physiological estrogen replacement in hypogonadism should not be s t a r t e d l a t e , b u t a t t h e a p p r o p r i a t e BA in o r d e r t o ensure normal pubertal growth. D-Ser(t-Bu, 161-GnK-I EA (WE 766) h a s b e e n s t u d i e d i n p l a s m a a n d u r i n e a f t e r i n t r a n a s a l (IN,200 ug) o r s u b c u t a n e o u s (SC,10 ug/kg) a d m i n i s t r a t i o n s . A RIA f o r HOE 766 a n d its m e t a b o l i t e s h a s b e e n developed u s i n g
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EA ( G i f t o f Dr. J. R i v i e r ) a s t r a c e r a n d a n antiserum-to HOE 7 6 6 ( g i f t o f D r . H. F r a s e r ) .
C r o s s r e a c t i o n w i t h n a t i v e GnRH was o n l y 1.7 %. S e n s i t i v i t y was 1 p g / t u b e . I n 6 m a l e a d o l e s c e n t s , m e a n p l a s m a HOE 7 6 6 c o n c e n t r a t i o n (*SE) was 0.46k0.08 , 0.50f0.10, 0.28*0.04, 0.24*0.04, 0.13k0.03, and 0.08 f0.02 ng /ml, 30, 60, 90, 120 and 180 min. a f t e r IN a d m i n i s t r a t i o n . U r i n e e x c r e t i o n of HOE 766 m e t a b o l i t e s was 9.4*2.0 ug/4h. There was a good c o r r e l a t i o n b e t w e e n p l a s m a a n d u r i n e l e v e l s ( r = 0 . 9 2 ) . I n t h e s a m e 6 v o l u n t e e r s , plasma HOE 766 l e v e l s w e r e 21. 2&3.0, 25.9'0.8, 21.2 f 0 . 9 , 17.1f0.7, 12.8f1.1, 8.9*0.4, and 5.9q.8, 20, 40, 60, 120 , 180 a n d 240 min. a f t e r t h e SC i n j e c t i o n . I n two u i r l s w i t h ~r e c o c i o u s ~u b e r t v f o l l c m d d u r h 3 months w i t h IN R.BRAUNER*, E.THIBAUD*, P.CZERNICHOW, R.RAPPAPORT, P.BISHOF, PC.SIZONENK0. H6p. Enfants-Malades, 26 INSERM U.30,Paris,France ; HBp.Cantonal,Gen*ve,Suisse R e s u l t s Of t r e a t m e n t w i t h an LHRH a g o n i s t (HOE 766) i n t r u e precocious p u b e r t y (P.P.)
The e f f i c i e n c y o f D-SER(TBU)6-LHRH 1-9 EAlO(Buserelin,HOE 766) was assessed i n 6 c h i l d r e n ( 5 g i r l s , l boy) with P.P. [idiopathic ( 2 ) ,hypothalamic hamartoma(2) ,arachnoid c y s t (1 ) ,hydrocephaly (1 f l .
Age a t beginning of t r e a t m e n t , was 4 10/12 t o 8 5/12 y r w i t h advanced bone age between 3 1/12 and 6 2/12 y r ; a l l g i r l s had menstruated. The boy was s u c c e s s f u l l y t r e a t e d by i n t r a n a s a l r o u t e (200 pg t.i.d.1 with serum T f a l l i n g (3.6 t o 0.2 ng/ml) and t e st i c u l a r volume r e g r e s s i o n . The 5 g i r l s r e c e i v e 20 pg/kg/d s c and r e s u l t s a t 6 mo therapy a r e shown below (meanzsem) ; i n 4 g i r l s seen a t 9 mo E, was maintained below 20 pg/ml;l g i r l with hydrocephaly was poorly c o n t r o l l e d . The growth r a t e (n=6) c a l c u l a t e d over 9 mo decreased from 9.1 + 0.6 t o 6.6 + 0.6*** cm/v. The B domain of I n s u l i n -l i k e Growth Factor I (IGF-I) i s recognized by IGF c a r r i e r p r o t e i n s but not by type I1 IGF r e c e p t o r s .
IGF-I and IGF-I1 a r e h i g h l y homologous t o each o t h e r and t o p r o i n s u l i n . Although t h e IGFs and i n s u l i n have s i m i l a r b i o l o g i c a l a c t i v i t i e s and r e c e p t o r r e a c t i v i t y , IGF c a r r i e r p r o t e i n s and one subtype of IGF r e c e p t o r s (Type 11) i n t e r a c t e x c l u s i v e l y w i t h t h e IGFs and not w i t h i n s u l i n . To determine t h e s t r u c t u r a l b a s i s f o r t h i s s p e c i f i c i t y , we have prepared 3 s y n t h e t i c hybrid molecules t h a t combine d i f f e r e n t p o r t i o n s of t h e IGF and i n s u l i n molecules: A27(Ins)-B(Ins), i n which t h e A c h a i n of i n s u l i n i s extended by t h e D domain of IGF-11; A(Ins)-B(IGF-I) and A27(Ins)-B(IGF-1)in which t h e B domain of IGF-I i s combined w i t h t h e n a t u r a l o r extended A chain of i n s u l i n . I n a competitive bindin%23ssay w i t h a c i d s t r i p p e d c a r r i e r p r o t e i n from a d u l t r a t serum, I-rIGF-I1 binding was i n h i b i t e d by t h e IGFs and by both hybrid molecules containing B-(IGF-I),
but not by i n s u l i n o r A27(Ins)-B(1ns). Q u a l i t a t i v e l y s i m i l a r r e s u l t s were obtained w i t h c a r r i e r p r o t e i n s from human serum, neonatal r a t serum and r a t l i v e r c e l l conditioned med By c o n t r a s t , none of t h e t h r e e hybrids molecules i n h i b i t e d "51-rIGF-II binding t o Type I1 IGF r e c e p t o r s on r a t l i v e r , p l a c e n t a o r chondrosarcoma c e l l s .
CONCLUSIONS: The B domain of IGF-I but not t h e D domain of IGF-I1 allow Insulin-IGF hybrid molecules t o be recognized by IGF c a r r i e r p r o t e i n s . Neither domain i s involved i n binding t o Type I1 IGF r e c e p t o r s . R. Hiimmelink*, U. Meijer*, M. Boucher*, W.G. Sippell
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Paed. Endocrine Unit, Univ. Dept. of Paediatrics, Kiel, W.-Germany. Pulsatile administration of GRF 1-44 to male patients with Growth-hormone-deficiency and normal men. We investigated the possibility of inducing a physiological G H pattern by exogenous administration of GRF 1-44 in a pulsatile manner in order t o modify the condition resulting from a hy othalamic defect. Three adolescent patients with short stature a n f four normal men responded t o a pulsatile i.v.-administration of GRF 1-44 with a clear increase in the GH levels. No ~a t i e n t was on GH t h e r a~v a t the time of the study. After a 12 hour nocturnal plasma profile O?.GH, cortisol, PRL and glucose (blood samples every 20 min) all subjects received 50 1.18 GRF 1-44 i.v. a t 8 and 10 a.m. and every second hour for 12 hours during the following night. Blood samples were taken every 20min t o evaluate pituitary res onse. Results: Patient 1 did not show any spontaneous nocturnal GR pulses but responded to pulsatile GRF stimulation with GH levels of 1.5 to 6.7 nglml in the morning and from 3.0 t o 15.8 ng/ml a t night, thus proving hypothalamic GRF deficiency. Patients 2 and 3 both had 4-5 spontaneous nocturnal GH peaks ranging from 8-40 ngfml. GH responses t o pulsatile GRF were between 10.4 and 109 ng/ml a t morning and between 12.3 and 114 ng/ml during the night. The characteristic circadian plasma profiles of cortisol, PRL and glucose remained intact. In the volunteers, sDontaneous nocturnal GH k e a t m e n t , & h e excretibn o f GOE 766 was i n b o o d c o r r e l a t i o n peaks ranged from 5.8-17.5 ngfml, whereas GH responses t o pulsatile w i t h t h e d e g r e e o f i n h i b i t i o n o f E2 and o f IH -and FSH responses GRF peaked a t 9.1-54 ng/ml in the mornin and a t 20-73 ng/ml during to GnRH. me monitoring of HOE 766 in the urine the n~ght. Conclusions: Our preliminary resuits suggest (1) that pituitary sensitivity t o exogenous pulsatile GRF is markedly higher during thus appears to be for the Of the intranasal the night than in the morning and (2) that a normal circadian GH t h e r a p y o f precocious puberty with GnRH analog.
pattern can be induced in GRF deficient patients by pulsatile GRF.
